Search Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologyProtocol groupHematologic Diseases (ped.)DiseaseJuvenile XanthogranulomaLangerhans Cell HistiocytosisRosai-Dorfman DiseaseSubgroupICD10C96.0C96.5C96.6D76.3MeSHHistiocytosis, Langerhans-CellSequenceChemotherapyChemo-substanceClofarabinChemo-substanceClofarabinChemo-substanceClofarabinChemo-substanceClofarabinNo. Substances1 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneFilgrastimGranisetronNo. Substances4Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationRelapse therapyTherapy phaseInductionTherapy intentioncurativeRisksAnemia Hb below 8g/dlEmetogenicityFebrile NeutropeniaInfectionsNeutropeniaThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorSimko SDiseaseLCH, JXG, RDD, Rezidivtherapie, im Median 22 Monate altOriginBaylor College of Medicine, Houston, TexasProtocols in Revision 1 protocol foundProtocols under revision.PAED Clofarabin 25, Langerhans Cell Histiocytosis (PID80 V1.1)
